Cancer treatment Scheduled Frequency | Secondary malignant neoplasm of female breast | ixabepilone | Prior Chemotherapy Quantity Neoplasm Metastasis
Item
scheduled to undergo cancer treatment for metastatic breast cancer (weekly or once every three weeks) with ixabepilone with no prior exposure to ixabepilone and no more than 2 prior chemotherapy regimens for metastatic disease
boolean
C0920425 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,3])
C0346993 (UMLS CUI [2])
C1135132 (UMLS CUI [3])
C1514457 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0027627 (UMLS CUI [4,3])
Serum calcium measurement
Item
serum calcium =< 1.2 x unl
boolean
C0728876 (UMLS CUI [1])
Serum magnesium measurement
Item
serum magnesium =< unl
boolean
C0202125 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine =< 1.5 x unl
boolean
C0201976 (UMLS CUI [1])
Informed Consent | Comprehension Clinical Trial placebo-controlled
Item
ability to sign informed consent and understand the nature of a placebo-controlled trial
boolean
C0021430 (UMLS CUI [1])
C0162340 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C1706408 (UMLS CUI [2,3])
ECOG performance status
Item
ecog performance status (ps) of 0, 1, or 2 (this form is on the mayo clinic cancer research consortium (mccrc) website https:/mccrc.mayo.edu/mccrc/forms/nonprotocolspecificforms/)
boolean
C1520224 (UMLS CUI [1])
Questionnaires Completion | Questionnaires Completion Assisted | Life Expectancy
Item
ability to complete questionnaire(s) by themselves or with assistance - life expectancy >= 4 months
boolean
C0034394 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0034394 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C1269765 (UMLS CUI [2,3])
C0023671 (UMLS CUI [3])
Central line placement Administration Calcium | Central line placement Administration Magnesium
Item
presence of a central line placed for administration of calcium and magnesium
boolean
C0919865 (UMLS CUI [1,1])
C1533734 (UMLS CUI [1,2])
C0006675 (UMLS CUI [1,3])
C0919865 (UMLS CUI [2,1])
C1533734 (UMLS CUI [2,2])
C0024467 (UMLS CUI [2,3])
Laboratory criteria
Item
please contact study investigator and/or consult protocol document for specific details on laboratory criteria
boolean
C0022885 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
Exclusion
Item
exclusion:
boolean
C0680251 (UMLS CUI [1])
Peripheral Neuropathy Pre-existing CTCAE Grades | Etiology Chemotherapy | Etiology Diabetes Mellitus | Etiology Alcohol | Etiology Toxin | Etiology Hereditary
Item
pre-existing history of peripheral neuropathy >= grade 2 (nci ctcae active version) due to any cause (chemotherapy, diabetes, alcohol, toxin, hereditary, etc.)
boolean
C0031117 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
C0015127 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0015127 (UMLS CUI [3,1])
C0011849 (UMLS CUI [3,2])
C0015127 (UMLS CUI [4,1])
C0001962 (UMLS CUI [4,2])
C0015127 (UMLS CUI [5,1])
C0040549 (UMLS CUI [5,2])
C0015127 (UMLS CUI [6,1])
C0439660 (UMLS CUI [6,2])
Anticonvulsants | Tricyclic Antidepressive Agents | Drugs used in neuropathic pain | Carbamazepine | Phenytoin | Valproic Acid | gabapentin | lamotrigine | Lidocaine Topical Product | Capsaicin Topical Cream | Treatment Neuropathy
Item
concurrent treatment with anticonvulsants, tricyclic antidepressants, or other neuropathic pain medications agents such as carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch, capsaicin cream, etc., or any other treatments specifically for prevention or treatment of neuropathy
boolean
C0003286 (UMLS CUI [1])
C0003290 (UMLS CUI [2])
C1319667 (UMLS CUI [3])
C0006949 (UMLS CUI [4])
C0031507 (UMLS CUI [5])
C0042291 (UMLS CUI [6])
C0060926 (UMLS CUI [7])
C0064636 (UMLS CUI [8])
C0360097 (UMLS CUI [9])
C1251865 (UMLS CUI [10])
C0087111 (UMLS CUI [11,1])
C0442874 (UMLS CUI [11,2])
Other medical condition Study Subject Participation Status At risk
Item
other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient
boolean
C3843040 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
Pregnancy | Breast Feeding | Childbearing Potential
Item
any of the following: pregnant women; nursing women; women of childbearing potential (per physician judgment)
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3])
Diabetes Mellitus Requirement Insulin | Diabetes Mellitus Requirement Hypoglycemic Agents
Item
diagnosed diabetes requiring insulin or oral hypoglycemic medications -
boolean
C0011849 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0021641 (UMLS CUI [1,3])
C0011849 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0020616 (UMLS CUI [2,3])
Digoxin | Digitoxin
Item
receiving digoxin or digitoxin
boolean
C0012265 (UMLS CUI [1])
C0012258 (UMLS CUI [2])
First degree atrioventricular block | Second degree atrioventricular block | Complete atrioventricular block
Item
history of heart block (any degree)
boolean
C0085614 (UMLS CUI [1])
C0264906 (UMLS CUI [2])
C0151517 (UMLS CUI [3])
Treatment Cardiac Arrhythmia
Item
current treatment for arrhythmias
boolean
C0087111 (UMLS CUI [1,1])
C0003811 (UMLS CUI [1,2])
Chemotherapeutic Agents Neuropathy
Item
concurrent treatment with other neuropathic chemotherapy agents
boolean
C0003392 (UMLS CUI [1,1])
C0442874 (UMLS CUI [1,2])